Analysts forecast that Kodiak Sciences Inc. (NYSE:KOD) will post earnings per share of ($0.44) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Kodiak Sciences’ earnings, with estimates ranging from ($0.56) to ($0.31). The firm is expected to report its next earnings report on Thursday, June 27th.

According to Zacks, analysts expect that Kodiak Sciences will report full year earnings of ($1.90) per share for the current financial year, with EPS estimates ranging from ($2.24) to ($1.68). For the next financial year, analysts forecast that the business will post earnings of ($2.10) per share, with EPS estimates ranging from ($2.65) to ($1.66). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Kodiak Sciences.

Kodiak Sciences (NYSE:KOD) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.25) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.05.

A number of research firms have weighed in on KOD. Zacks Investment Research lowered Kodiak Sciences from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Chardan Capital began coverage on Kodiak Sciences in a research note on Wednesday, February 20th. They set a “buy” rating and a $22.50 price objective on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $19.13.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American International Group Inc. acquired a new position in shares of Kodiak Sciences during the fourth quarter valued at about $44,000. Deutsche Bank AG acquired a new stake in Kodiak Sciences in the 4th quarter valued at $87,000. Bank of New York Mellon Corp acquired a new stake in Kodiak Sciences in the 4th quarter valued at $94,000. Pura Vida Investments LLC acquired a new stake in Kodiak Sciences in the 4th quarter valued at $173,000. Finally, Geode Capital Management LLC bought a new position in shares of Kodiak Sciences in the 4th quarter valued at about $458,000.

Shares of NYSE:KOD traded down $0.08 during trading on Monday, reaching $6.98. The stock had a trading volume of 35,800 shares, compared to its average volume of 68,603. Kodiak Sciences has a 1-year low of $5.65 and a 1-year high of $11.10.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Featured Article: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with's FREE daily email newsletter.